Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery

Gordon
2010 Oncology Reports  
The advent of pathotropic (disease-seeking) targeting has transported genetic medicine across the threshold of history with the progressive clinical validation of Rexin-G, a tumor-targeted nanosized anti-cancer agent. Achieving noteworthy single-agent efficacy and survival benefits in otherwise intractable cancers, the molecular biotechnology platform has stimulated intense interest in the underlying mechanisms-of-action. This report exhibits the effective localization of Rexin-G nanoparticles
more » ... in-G nanoparticles within a metastatic liver lesion, as observed upon its surgical excision.
doi:10.3892/or_00000926 fatcat:b6uxr3ftnzatrnnbu4b2tmkbli